Acquisition Announced
Gilead acquisition of Ouro Medicines
US$1.7bn consideration
Announced 24 Mar 2026
Advisers
Ouro Medicines
Target
- Legal adviser
- Goodwin

Team: Felipe M. Heiderich, Wei Xu, David R. Chen, Kingsley L. Taft, Sam Beavers, Bartek Sudol, Andrea Akinbola, Ruowen Li, Daniel Karelitz, Matthew Dunay, Katerina Stavrianidis, Kevin Kabler, Malhar Naik, Alex Fisher, Alex Nicolaidis, Julie Tibbets, Matthew Wetzel, Arman Oruc, Anuj Ghai, Kevin Walsh, Jacob Osborn, Gozde Guckaya, Anna Sofia Polishchuk
- Target
- Ouro Medicines
- Acquirer
- Gilead
- Target based in
- United States
- Buyer based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Drug Development
In the league tables
Similar deals
- Lilly acquisition of Vaccine Company May 2026 · US$1.6bn · Biotech
- Servier acquisition of Sevasemten and Edgewise muscular dystrophy business Jun 2026 · US$1.6bn · Biotech
- Eli Lilly acquisition of Curevo Vaccine May 2026 · US$1.5bn · Biotech
- Novartis acquisition of Pikavation Mar 2026 · US$2bn · Biotech
- UCB acquisition of Candid Therapeutics May 2026 · US$2.2bn · Biotech
Sources
- 2026 Centerview Partners: Exclusive financial advisor to Gilead on its acquisition of Ouro Medicines centerviewpartners.com
- 24 Mar 2026 Goodwin Advises Ouro Medicines on Acquisition by Gilead Sciences for $1.675 Billion Upfront and Up To $500 Million in Milestones for a Total of Up To $2.375 Billion goodwinlaw.com
- 31 Mar 2026 Galapagos to Collaborate With Gilead Sciences on Ouro Medicines Assets paulweiss.com

